Publications by authors named "Michele Aieta"

Claim this Profile
P
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Laura Orlando, Evaristo Maiello, Michele Orditura, Anna Diana, Giuliano Antoniol, Michele Aieta

Breast· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario.
Giuseppe Di Lorenzo, Aieta Michele, Leo Silvana, Domenico Bilancia, Rossella Di Trolio

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Michele Aieta

Clin Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, Samanta Sarti, Santino Minichillo, Michele Aieta

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Luca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, Salvatore Pisconti, Sabrina Rossetti, Michele Aieta

Tumori· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers.
Simona Laurino, Mariarita Brancaccio, Tiziana Angrisano, Giovanni Calice, Sabino Russi, Michele Aieta

Biomedicines· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Francesca Vignani, Rosa Tambaro, Ugo De Giorgi, Patrizia Giannatempo, Davide Bimbatti, Michele Aieta

Eur Urol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy.
Alfredo Tartarone, Rosa Lerose, Marina Tartarone, Michele Aieta

Life (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.
Anna Passarelli, Giovanna Galdo, Teresa Pellegrino, Giandomenico Roviello, Michele Aieta

Dermatol Reports· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR99021, trough GSK-3β Targeting, Reduces Epithelioid Sarcoma Cell Proliferation by Activating Mitotic Catastrophe and Autophagy.
Sabino Russi, Alessandro Sgambato, Anna Maria Bochicchio, Pietro Zoppoli, Michele Aieta

Int J Mol Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Umberto Basso, Antonella Facchinetti, Elisabetta Rossi, Marco Maruzzo, Vincenza Conteduca, Michele Aieta

Oncologist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro, Claudia Mucciarini, Michele Aieta

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.
Anna Passarelli, Michele Aieta, Alessandro Sgambato, Cesare Gridelli

Front Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas.
Valentina Condelli, Giovanni Calice, Alessandra Cassano, Michele Basso, Maria Grazia Rodriquenz, Michele Aieta

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.
Elisabetta Rossi, Michele Aieta, Alfredo Tartarone, Aldo Pezzuto, Antonella Facchinetti

Transl Lung Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Giandomenico Roviello, Monica Ramello, Martina Catalano, Alberto D'Angelo, Raffaele Conca, Michele Aieta

Sci Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Anna Passarelli, Giovanna Galdo, Michele Aieta, Tommaso Fabrizio, Antonio Villonio

Int J Mol Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Michele Aieta

Breast· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Margaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Michele Aieta

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Mariangela Ciccarese, Laura Orlando, Palma Fedele, Paola Schiavone, Evaristo Maiello, Michele Aieta

Breast J· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer.
Giandomenico Roviello, Raffaele Conca, Alberto D'Angelo, Andrea Giovanni Multari, Giovanni Paganini, Michele Aieta

Anticancer Drugs· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focus on lung cancer screening.
Alfredo Tartarone, Rosa Lerose, Michele Aieta

J Thorac Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Evaristo Maiello, Gabriele Di Maggio, Stefano Cordio, Saverio Cinieri, Francesco Giuliani, Michele Aieta

Clin Colorectal Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Alessandro Russo, Marco Russano, Tindara Franchina, Maria R Migliorino, Giuseppe Aprile, Michele Aieta

Adv Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Francesco Pantano, Marco Russano, Alfredo Berruti, Giovanni Mansueto, Maria R Migliorino, Michele Aieta

Expert Opin Biol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis